Global Tildrakizumab Market Size, Share and Trends Analysis Report, By Type (Prefilled 100 mg/mL solution and Type II), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2022-2028)

The global tildrakizumab market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Tildrakizumab is a monoclonal antibody used to treat inflammatory diseases caused by the lack of immunity. Various diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis can be treated with tildrakizumab (AS). One of the major factors driving the demand of the tildrakizumab drug is the rising prevalence of atopic illnesses such as psoriasis, ecthyma, and eczema, among others.

Additionally, skin irritants occur due to the use of certain soaps, detergents, perfumes, and other skin & beauty products. Thus, allergic reactions is another major factor that are increasing the burden of atopic dermatitis and driving the growth of the tildrakizumab market. For instance, in May 2018, the US Food and Drug Administration (USFDA) approved Sun Pharmaceuticals’ biologics license application (BLA) for ILUMYA. Schering-Plough merged with Merck & Co, a US-based pharmaceutical company, and developed the medication. Merck & Co. sold Sun Pharmaceuticals’ the global rights to ILUMYA for $80 million. Adults with moderate-to-severe plaque psoriasis should use ILUMYA (tildrakizumab-asmn), a subcutaneous infusion.

Prefilled 100 mg/mL solution is a tildrakizumab product with a dose strength of 100 mg/mL. This type is used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy candidates along with insufficient responders to conventional systemic therapies. It can also be used in tandem with other systemic treatments. Another form of tildrakizumab product is Type II, which has a dose strength of 100 mg/mL. It works by preventing the immune system from attacking healthy cells and tissues by blocking a specific protein found in the body. This minimizes psoriasis-related chronic inflammation which in turn boosts the market growth.

During the projection period, hospital pharmacies are expected to have a significant market share. The increasing number of prescriptions for psoriasis therapy and attractive health reimbursement is responsible for the domination. In hospitals, tildrakizumab is used to treat moderate to severe plaque psoriasis and psoriasis vulgaris. People with chronic illnesses that require particular attention, nursing care, or long-term rehabilitation go to the hospital. On the other hand, due to improved patient convenience, increased use of e-commerce, and attractive discounts and coupons on online sales, online pharmacies are expected to grow at a large rate.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Indication
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- NCK Pharma Solution Ltd., Almirall, S.A, Sun Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tildrakizumab Market Report by Segment

By Type

• Prefilled 100mg/mL solution
• Type II

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Tildrakizumab Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America

Middle East & Africa